Disease · MONDO_0008159

postmenopausal osteoporosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. postmenopausal osteoporosis. Diseases, record MONDO_0008159. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008159

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: postmenopausal osteoporosis; Open Targets
Open Targets ID: MONDO_0008159; Open Targets
Other names: Bone Loss, Perimenopausal, Bone Loss, Postmenopausal, Bone Losses, Perimenopausal, Bone Losses, Postmenopausal, Osteoporoses, Post-Menopausal, Osteoporoses, Postmenopausal, Osteoporosis, Post Menopausal, Osteoporosis, Postmenopausal, Perimenopausal Bone Loss, Perimenopausal Bone Losses, Post-Menopausal Osteoporoses, Post-Menopausal Osteoporosis, Postmenopausal Bone Loss, Postmenopausal Bone Losses, Postmenopausal Osteoporoses; Open Targets
MeSH: D015663; MeSH
Highest stage of its drugs: Approval, for 20 of its 24 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ALENDRONIC ACID	CHEMBL870	Small molecule	Approval	EMA Human Drugs	6	3	3	Drugs and targets
IBANDRONIC ACID	CHEMBL997	Small molecule	Approval	EMA Human Drugs	6	3	3	Drugs and targets
DENOSUMAB	CHEMBL1237023	Antibody	Approval	EMA Human Drugs and TTD	18	2	2	Drugs and targets
ZOLEDRONIC ACID	CHEMBL4303669	Small molecule	Approval	DailyMed and EMA Human Drugs	5	2	2	Drugs and targets
TERIPARATIDE	CHEMBL525610	Protein	Approval	EMA Human Drugs	7	1	1	Drugs and targets
IBANDRONATE SODIUM	CHEMBL3989569	Small molecule	Approval	DailyMed	8	0	0	Drugs and targets
RISEDRONATE SODIUM	CHEMBL1654	Small molecule	Approval	DailyMed	8	0	0	Drugs and targets
ALENDRONATE SODIUM	CHEMBL675	Small molecule	Approval	DailyMed and FDA	6	0	0	Drugs and targets
BAZEDOXIFENE ACETATE	CHEMBL2106615	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
CHOLECALCIFEROL	CHEMBL1042	Small molecule	Approval	EMA Human Drugs	3	0	0	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets8

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FDPS	Farnesyl pyrophosphate synthase	7	Farnesyl diphosphate synthase inhibitor	Approval	https://conductscience.org/library/genes/2224	Drugs and targets
ESR1	Estrogen receptor	6	Estrogen receptor agonist; Estrogen receptor alpha agonist; Estrogen receptor modulator	Approval	https://conductscience.org/library/genes/2099	Drugs and targets
ESR2	Estrogen receptor	5	Estrogen receptor agonist; Estrogen receptor beta modulator; Estrogen receptor modulator	Approval	https://conductscience.org/library/genes/2100	Drugs and targets
PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	3	Parathyroid hormone receptor agonist	Approval	https://conductscience.org/library/genes/5745	Drugs and targets
CALCR	Calcitonin receptor	2	Calcitonin receptor agonist	Approval	https://conductscience.org/library/genes/799	Drugs and targets
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Approval	https://conductscience.org/library/genes/7421	Drugs and targets
SOST	Sclerostin	1	Sclerostin inhibitor	Approval	https://conductscience.org/library/genes/50964	Drugs and targets
TNFSF11	Tumor necrosis factor ligand superfamily member 11	1	Tumor necrosis factor ligand superfamily member 11 inhibitor	Approval	https://conductscience.org/library/genes/8600	Drugs and targets

Trials14

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00541658	A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis	Phase 3	923	2011-06-21	Postmenopausal Osteoporosis	RISEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00545779	BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.	Phase 3	677	2016-10-28	Post-Menopausal Osteoporosis	IBANDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01652690	Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice		600	2016-05-26	Osteoporosis, Postmenopausal	DENOSUMAB	Its record names the disease	ClinicalTrials.gov
NCT00918749	Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women	Phase 2	205	2011-03-24	Postmenopausal Osteoporosis	RISEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00577720	Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate	Phase 2	181	2012-01-13	Postmenopausal Women	RISEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00361595	Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women	Not applicable	35	2011-01-14	Osteoporosis	ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01128257	A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis		6,054		Postmenopausal Osteoporosis	ALENDRONIC ACID, IBANDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00666627	Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects	Phase 2	410		Post-menopausal Osteoporosis	ALENDRONIC ACID, IBANDRONIC ACID, RISEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01155232	Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis		100		Osteoporosis	TERIPARATIDE	Its record names the disease	ClinicalTrials.gov
NCT04702204	Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients		73		Postmenopausal Osteoporosis	DENOSUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 14

See all 14 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Czech Republic vs Slovakia: Number of Participants Receiving All Prescriptions and Injections of Denosumab From the Initial Prescribing Physician's Office	295 of 300	296 of 300	600	NCT01652690	Trial comparisons
Czech Republic vs Slovakia: serious adverse events	0 of 300	1 of 300	600	NCT01652690	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
21947137	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008159

GET https://conductscience.org/api/diseases/v1/MONDO_0008159/drugs?page=2

API reference For AI assistants